- BioVaxys Technology (CSE:BIOV) has revealed SpayVac for Wildlife’s Madison, Wisconsin lab and production facility is now fully operational, supporting the production of its contraceptive vaccines, including SpayVac® and a new GnRH vaccine.
- Large-scale shipments have been made to support a European feral horse population management project and a Southeast Asian immunocontraception project
- SpayVac utilizes BioVaxys’ patented liposome-based antigen delivery technology, with plans to scale production and expand product development using BioVaxys’ platform for innovation
- Shares of BioVaxys Technology are up 7.69 per cent to C$0.07 as of 11:50 a.m. ET
BioVaxys Technology (CSE: BIOV) and SpayVac for Wildlife have announced that SpayVac’s laboratory and production facility in Madison, Wisconsin, is now fully operational and ready to supply its contraceptive vaccines, including the established pZP vaccinenand the new GnRH vaccine.
In a press release, the company stated this facility will serve the commercial aquaculture sector as well as other species in need of fertility control.
The new production capacity will support the broader availability of SpayVac vaccines for field trials, market seeding studies, and an upcoming launch. It will also enable the creation of new antigen formulations designed to meet diverse animal contraceptive needs.
SpayVac for Wildlife has emphasized the importance of this scaled-up production, which will be funded in part by proceeds from its ongoing fundraising efforts.
SpayVac for Wildlife has already made large-scale shipments to support a feral horse population management project in Europe, highlighting the global reach of their animal population control initiatives. Additionally, vaccines were produced earlier this year for an immunocontraception project in Southeast Asia.
“SpayVac for Wildlife is positioned to lead the field of breeding control, and with their expanded production capacity, they can accelerate product development and leverage BioVaxys’ technology platforms to create new innovations,” Kenneth Kovan, president and COO of BioVaxys Technology, said in a news release.
As it currently stands, the company’s progress in ongoing trials is in collaboration with both the U.S. government and the EU. The company is also working with an aquaculture genetics firm to explore an alternative to induced triploidy in fish, which can lead to sterility but also increases disease susceptibility.
The SpayVac platform utilizes a patented liposome-based antigen delivery technology licensed from BioVaxys, which has shown strong immune responses in multiple species. This single-dose, long-lasting vaccine is intended for wildlife, agricultural animals, and commercial aquaculture markets.
BioVaxys is also advancing its own vaccine programs based on the same liposome-based technology, targeting human diseases in the fields of infectious disease, oncology, and allergy, with several programs currently in clinical development.
Shares of BioVaxys Technology are up 7.69 per cent to C$0.07 as of 11:50 a.m. ET.
Join the discussion: Find out what everybody’s saying about this stock on the BioVaxys Technology Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image: Adobe Stock)
